Investment Considerations Nemaura’s flagship product, sugarBEAT®, is a wearable, non-invasive and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and prediabetes. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union, and Nemaura has submitted a premarket approval application to the U.S. FDA. Nemaura … Continue reading “Nemaura Medical Inc. (NASDAQ: NMRD)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |